Letestuianin C

Letestuianin C

SCHEMBL4410123

O=C(CCc1ccc(O)cc1)CC(=O)CCc1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL1 P55085 1/20 0.60
HDAC2 Q92769 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
ESR1 P03372 2/20 0.56
ESR2 Q92731 1/20 0.56
KDM4E B2RXH2 3/20 0.53
CYP19A1 P11511 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ALDH1A1 P00352 2/20 0.53
CYP2C19 P33261 2/20 0.53
SLC16A3 O15427 1/20 0.53
LMNA P02545 1/20 0.53
TTR P02766 1/20 0.53
TP53 P04637 1/20 0.53
CYP1A2 P05177 1/20 0.53
POLB P06746 1/20 0.53
CYP3A4 P08684 1/20 0.53
GAA P10253 1/20 0.53
CYP2D6 P10635 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13311578 0.92 TRPV1 (0.64) F2RL1HDAC2HDAC8CYP19A1ALDH1A1
SCHEMBL8108885 0.91 ESR1 (0.62) F2RL1HDAC2HDAC8ESR1ESR2
SCHEMBL4409944 0.90 F2RL1 (0.56) F2RL1HDAC2HDAC8ESR1ESR2
SCHEMBL2862583 0.90 MMP12 (0.68) F2RL1HDAC2HDAC8ESR1ESR2
SCHEMBL31322120 0.89 F2RL1 (0.64) F2RL1HDAC2HDAC8ESR1ESR2
SCHEMBL1645396 0.88 KDM4E (0.55) F2RL1HDAC2HDAC8ESR1ESR2
SCHEMBL12601802 0.87 IAPP (0.65) ESR1KDM4ECYP19A1MEN1KMT2A
SCHEMBL15936319 0.86 TRPV1 (0.63) HDAC2HDAC8MAPK1MMP12TRPV1
SCHEMBL3217413 0.86 BACE1 (0.53) F2RL1HDAC2HDAC8MEN1KMT2A
SCHEMBL452806 0.84 TDP1 (0.59) HDAC2HDAC8ESR1ESR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4045478-B1 CURCUMINOID COMPOSITION AND ITS THERAPEUTIC POTENTIAL IN MANAGING LUNG FIBROSIS SAMI SABINSA GROUP LTD (IN) 2026-01-28 EP claimed
EP-4045478-A1 CURCUMINOID COMPOSITION AND ITS THERAPEUTIC POTENTIAL IN MANAGING LUNG FIBROSIS Sami-Sabinsa Group Limited (IN) 2022-08-24 EP claimed
CN-114246849-A Curcumin-peptide conjugates and formulations thereof 奥斯生化药剂公司 2022-03-29 CN claimed
US-20090318565-A1 Novel Compositions for the Enhancement of the Anti-oxidant Potential of Hydrogenated Curcuminoids or Combinations Thereof MAJEED MUHAMMED 2009-12-24 US claimed
US-6875426-B2 Self-tanning composition containing a tetrahydrocurcuminoid and a self-tanning agent L'OREAL (FR) 2005-04-05 US claimed
US-6872401-B2 Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil L'OREAL (FR) 2005-03-29 US claimed
US-20040009200-A1 Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil SOCIETE L'OREAL S.A. (FR) 2004-01-15 US claimed
US-20030228268-A1 Self-tanning composition containing a tetrahydrocurcuminoid and a self-tanning agent SOCIETE L'OREAL S.A. (FR) 2003-12-11 US claimed
EP-1348424-A1 Self-tanning composition containing a tetrahydrocurcumine derivative and a self-tanning agent L'OREAL (FR) 2003-10-01 EP claimed
EP-1348418-A1 Cosmetical or dermatological composition containing a tetrahydrocurcumin derivative and an oil bearing an amide group L'OREAL (FR) 2003-10-01 EP claimed
EP-4743071-A2 DIPHENYLETHYLENE COMPOUNDS AND COMPOSITIONS THEREOF INNOVENE INC. (US) 2026-05-20 EP disclosed
EP-4045478-B1 CURCUMINOID COMPOSITION AND ITS THERAPEUTIC POTENTIAL IN MANAGING LUNG FIBROSIS SAMI SABINSA GROUP LTD (IN) 2026-01-28 EP disclosed
US-20250206788-A1 CURCUMIN-PEPTIDE CONJUGATES AND FORMULATIONS THEREOF CHANCEY, John (US) 2025-06-26 US disclosed
US-12247054-B2 Curcumin-peptide conjugates and formulations thereof HAUS BIOCEUTICALS, INC. 2025-03-11 US disclosed
WO-2025015023-A2 DIPHENYLETHYLENE COMPOUNDS AND COMPOSITIONS THEREOF INNOVENE, INC. (US) 2025-01-16 WO disclosed
US-5208251-A Compounds for antiinflammatory agents, antiallergens, antiarthritic, antiulcer agents WARNER-LAMBERT COMPANY (US) 1993-05-04 US disclosed
EP-0245825-B1 STYRYL PYRAZOLES, ISOXAZOLES AND ANALOGS THEREOF HAVING ACTIVITY AS 5-LIPOXY-GENASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM WARNER-LAMBERT COMPANY (US) 1991-03-13 EP disclosed
US-4924002-A REACTION WITH MOLYBDENUM CARBONYL AND HYDRAZINE WARNER-LAMBERT COMPANY (US) 1990-05-08 US disclosed
US-4877881-A SUNSCREEN WARNER-LAMBERT COMPANY (US) 1989-10-31 US disclosed
EP-0245825-A1 Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them WARNER-LAMBERT COMPANY (US) 1987-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030228268-A1 Self-tanning composition containing a tetrahydrocurcuminoid and a self-tanning agent TYR, TES, TERT F2RL1 3615/4885HDAC2 2042/4885HDAC8 1229/4885
US-20090318565-A1 Novel Compositions for the Enhancement of the Anti-oxidant Potential of Hydrogenated Curcuminoids or Combinations Thereof GPX4, HMOX1, GPX1 F2RL1 4334/4885HDAC2 748/4885HDAC8 1026/4885
US-20040009200-A1 Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil KRT18, DHCR24, FABP4 F2RL1 1733/4885HDAC2 1687/4885HDAC8 1098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.